Nov. 17 (Sat) 08:30-10:00 |
Viral hepatitis |
R2A (3F) |
Chairperson(s) |
Heon Ju Lee (Daegu), Yoon Jun Kim (Seoul) |
|
08:30-08:36 |
Patient tolerability of Interferon and Interferon free regimen for hepatitis C infection |
Dexton Johns (Malapuram) |
08:36-08:42 |
Increasing age and comorbidities in a population-based study of chronic hepatitis b (chb) patients from 2007 to 2016 in korea |
Dae Won Jun (Seoul) |
08:42-08:48 |
Intrafamilial seroprevalence of hepatitis B surface antigen of chronic hepatitis B patients in Bangladesh |
Md. Yasir Arafat (Dhaka) |
08:48-08:54 |
An open-label, randomized, active-control trial of 8-week versus 12-week elbasvir/grazoprevir in nave HCV genotype-1b patients with mild fibrosis (EGALITE) |
Ming-Lung Yu (Kaohsiung) |
08:54-09:00 |
Cirrhosis related to chronic hepatitis C virus infection and factors associated in treatment-naive hepatitis C patients |
Nikko Darnindro (Jakarta) |
09:00-09:06 |
APRI and FIB-4 have good predictive value for significant fibrosis in subjects with concomitant chronic hepatitis B and hepatic steatosis. |
Kenneth Weicong Lin (Singapore) |
09:06-09:12 |
Treatment of patients with chronic hepatitis c genotype 3 infection with or without cirrhosis with sofosbuvir and velpatasvir with or without ribavirin |
Sonny Bherwani (Ahmedabad) |
09:12-09:18 |
Long-term follow up of chronic hepatitis C Egyptian patients treated with sofosbuvir/daclatasvir regimen |
Karim Elnoemany (Shebin Elkom) |
09:18-09:24 |
The utility of HCV Ag as a marker to assess active HCV infection in individuals with genotype 4 HCV in Egypt |
Karim Elnoemany (Shebin Elkom) |
09:24-09:30 |
Risk of hepatocellular carcinoma among chronic hepatitis B patients presumed in immune tolerant phase |
Dong Hyun Sinn (Seoul) |
09:30-09:36 |
Sofosbuvir and velpatasvir for chronic HCV genotype 3 infection compared to sofosbivir and daclatasvir |
Neehar M Shanavas (Trivandrum) |
09:36-09:42 |
The prevalence of non-alcoholic fatty liver disease in patients with chronic hepatitis B and its associated characteristics |
Khairul Najmi Muhammad Nawawi (Bandar Tun Razak) |
09:42-09:48 |
Changes in phospho-proteome of splenic macrophages from patients with hypersplenism due to portal hypertension |
Shu Zhang (Xi'an) |
09:48-09:54 |
Sofosbuvir in combination with ribavirin in genotype 3 hepatitis C patients with cirrhosis. An experience from tertiary care hospital |
Ali Akbar Langhah (Karachi) |